Skip to main content

Table 5 Clinical studies in other cancer types

From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Cancer type

Patients

Trial, ID

Follow-up

Outcomes

Reference

Malignant pleural mesothelioma

Previously treated

Phase 2

NCT03048474

> 12 months

ORR, 38%

Median PFS, 6.2 months

6-month PFS rate, 50%

Median OS, not reached

12-month OS rate, 64%

Grade 3-4 AEs, 38%

Disselhorst et al 2019

Malignant pleural mesothelioma

Previously treated

Phase 2

NCT02716272

> 16 months

ORR, 28%

Median PFS, 5.6 months

12-month PFS rate, 23%

Median OS rate, 15.9 months

12-month OS rate, 58%

Grade 3-4 AEs, 26%

Scherpereel et al 2019

Unresectable Sarcoma

Previously treated

Phase 2

NCT02500797

> 12 months

Confirmed response, 16%

Median PFS, 4.1 months

Median OS, 14.3 months

Grade 3-4 AEs, 14%

D’Angelo et al 2018

Esophagogastric cancer

Previously treated

Phase 1/2

NCT01928394

 

Investigator assessed ORR, 24%

Median PFS, 1.4 months

12-month PFS rate, 17%

Median OS, 6.9 months

18-month OS rate, 28%

Grade 3-4 AEs, 35%

Janjigian et al 2018

Prostate cancer

Previously treated, AR-V7 positive

Phase 2

NCT02601014

≥ 1.9 months

ORR, 25%

Median PFS,3.7 months

Median OS, 8.2 months

Grade 3-4 AEs, 46%

Boudadi et al 2018